United Therapeutics CEO Martine Rothblatt Sells Shares
Martine Rothblatt sold 9,500 shares of United Therapeutics for over $5.22 million.
Key Points
- Martine Rothblatt, CEO of United Therapeutics, sold 9,500 shares on June 16, 2026, for about $5.22 million.
- Shares of UTHR traded near $548.27, with a market cap of $23.27 billion and a P/E ratio of 20.28.
- United Therapeutics focuses on treatments for life-threatening diseases, with products like Tyvaso and Remodulin.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, sold 9,500 shares of the company on June 16, 2026. The shares were sold at an average price of $549.80, totaling approximately $5.22 million. This transaction was planned under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks.
United Therapeutics Corporation Stock Up 7.0%
Shares of United Therapeutics, traded on the NasdaqGS under the ticker UTHR, were priced around $548.27. The company boasts a market capitalization of about $23.27 billion and a price-to-earnings (P/E) ratio of 20.28. The stock's 52-week range is between $272.12 and $609.35, with a 50-day moving average of $566.59 and a 200-day moving average of $495.58. United Therapeutics has a beta of 0.573, indicating lower volatility compared to the market.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent financial results, United Therapeutics reported revenue of approximately $3.17 billion, with a slight decline of 1.6% compared to the previous period. The company achieved a net margin of 40.62% and a return on equity (ROE) of 20.26%. The earnings per share (EPS) stood at $27.03. Investors can look forward to the next earnings release scheduled for July 29, 2026.
About United Therapeutics
United Therapeutics Corporation, headquartered in Silver Spring, Maryland, is a biotechnology company that develops and sells products for chronic and life-threatening diseases. Its portfolio includes treatments like Tyvaso DPI and Remodulin for pulmonary arterial hypertension, as well as Unituxin for neuroblastoma. The company is also involved in developing innovative solutions for organ transplantation and regenerative medicine. Founded in 1996, United Therapeutics is led by CEO Dr. Martine A. Rothblatt and employs around 1,400 people.
Bottom Line
The recent insider sale by Martine Rothblatt is part of a planned trading strategy and reflects typical activity for company executives. United Therapeutics continues to be a significant player in the healthcare industry, focusing on unmet medical needs. As always, remember that 13F filings and insider transactions provide a historical view and may not represent current positions.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.